Adamis Pharmaceuticals announced that it has initiated a phase II/III study to evaluate Tempol, its investigational oral antiviral, for the treatment of COVID-19.
The phase II/III study will enroll approximately 248 adult participants who have tested positive for COVID-19 within five days of study and have at least one co-morbidity that is not life-threatening.
The study will randomize participants into two equal groups to evaluate Tempol in comparison with placebo. The primary endpoint of this study is to compare the hospitalization rate of patients receiving tempol with placebo. The participantsselected for tempol will receive two doses of tempol (400mg) per day for a period of up to 21 days.
Shares of Adamis rose 2.7% following the news. In fact, the stock has rallied 135% so far this year against the industry’s decline of 9.2%.
Per the company, tempol has the potential of reducing COVID-19 symptoms by calming inflammation, protecting organs from damage and decreasing the clumping of platelets. The candidate demonstrated anti-inflammatory and antioxidant activity in pre-clinical studies. Per a study conducted by the company in collaboration with Standford University, Tempol demonstrated strong in-vitro anti-cytokine activity in inhibiting multiple cytokines from the cells of COVID-19 patients.
We inform investors that Adamis in-licensed tempol from Matrix. The license includes the worldwide use of Tempol for the treatment of all respiratory diseases, including asthma, respiratory syncytial virus, influenza and COVID-19.
Please note that multiple companies are developing orally administered antiviral candidates for COVID-19. Earlier this week, Merck (MRK - Free Report) announcedthat it has initiated a pivotal phase III MOVe-AHEAD study to evaluate molnupiravir, its investigational oral antiviral, for the prevention of COVID-19. Pfizer (PFE - Free Report) is also developing an antiviral candidate for COVID-19, which is currently being evaluated in a phase II/III study.
Gilead Sciences’ (GILD - Free Report) Veklury (remdesivir) is an FDA approved antiviral for COVID-19, administered intravenously.
Apart from Tempol, Adamis’ pipeline includes its epinephrine injection, Symjepi, which has been approved for the emergency treatment of acute allergic reactions, including anaphylaxis. Also, the company’s new drug application for Zimhias — a potential treatment for opioid overdose — is currently under review by the FDA.
Zacks Rank
Adamis presently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks Naming Top 10 Stocks for 2024
Want to be tipped off early to our 10 top picks for the entirety of 2024?
History suggests their performance could be sensational.
From 2012 (when our Director of Research, Sheraz Mian assumed responsibility for the portfolio) through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2024. Don’t miss your chance to get in on these stocks when they’re released on January 2.
Be First to New Top 10 Stocks >>
Adamis Pharmaceuticals announced that it has initiated a phase II/III study to evaluate Tempol, its investigational oral antiviral, for the treatment of COVID-19.
The phase II/III study will enroll approximately 248 adult participants who have tested positive for COVID-19 within five days of study and have at least one co-morbidity that is not life-threatening.
The study will randomize participants into two equal groups to evaluate Tempol in comparison with placebo. The primary endpoint of this study is to compare the hospitalization rate of patients receiving tempol with placebo. The participantsselected for tempol will receive two doses of tempol (400mg) per day for a period of up to 21 days.
Shares of Adamis rose 2.7% following the news. In fact, the stock has rallied 135% so far this year against the industry’s decline of 9.2%.
Per the company, tempol has the potential of reducing COVID-19 symptoms by calming inflammation, protecting organs from damage and decreasing the clumping of platelets. The candidate demonstrated anti-inflammatory and antioxidant activity in pre-clinical studies. Per a study conducted by the company in collaboration with Standford University, Tempol demonstrated strong in-vitro anti-cytokine activity in inhibiting multiple cytokines from the cells of COVID-19 patients.
We inform investors that Adamis in-licensed tempol from Matrix. The license includes the worldwide use of Tempol for the treatment of all respiratory diseases, including asthma, respiratory syncytial virus, influenza and COVID-19.
Please note that multiple companies are developing orally administered antiviral candidates for COVID-19. Earlier this week, Merck (MRK - Free Report) announcedthat it has initiated a pivotal phase III MOVe-AHEAD study to evaluate molnupiravir, its investigational oral antiviral, for the prevention of COVID-19. Pfizer (PFE - Free Report) is also developing an antiviral candidate for COVID-19, which is currently being evaluated in a phase II/III study.
Gilead Sciences’ (GILD - Free Report) Veklury (remdesivir) is an FDA approved antiviral for COVID-19, administered intravenously.
Apart from Tempol, Adamis’ pipeline includes its epinephrine injection, Symjepi, which has been approved for the emergency treatment of acute allergic reactions, including anaphylaxis. Also, the company’s new drug application for Zimhias — a potential treatment for opioid overdose — is currently under review by the FDA.
Zacks Rank
Adamis presently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks Naming Top 10 Stocks for 2024
Want to be tipped off early to our 10 top picks for the entirety of 2024?
History suggests their performance could be sensational.
From 2012 (when our Director of Research, Sheraz Mian assumed responsibility for the portfolio) through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2024. Don’t miss your chance to get in on these stocks when they’re released on January 2.
Be First to New Top 10 Stocks >>
Get the latest research report on PFE - FREE
Get the latest research report on MRK - FREE
Get the latest research report on GILD - FREE